AstraZeneca’s (AZN) Buy Rating Reiterated at Citigroup

Citigroup reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Wednesday morning, Digital Look reports. Citigroup currently has a £100 ($130.67) target price on the biopharmaceutical company’s stock, up from their previous target price of GBX 7,000 ($91.47).

A number of other research firms have also issued reports on AZN. Societe Generale reaffirmed a buy rating on shares of AstraZeneca in a report on Tuesday, September 10th. Barclays raised their target price on AstraZeneca from GBX 7,800 ($101.92) to GBX 8,000 ($104.53) and gave the company an overweight rating in a report on Friday, September 6th. Jefferies Financial Group reaffirmed a neutral rating on shares of AstraZeneca in a report on Thursday, August 29th. UBS Group reissued a sell rating and set a GBX 5,700 ($74.48) price objective on shares of AstraZeneca in a report on Tuesday, September 10th. Finally, Bryan, Garnier & Co reissued a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. AstraZeneca currently has a consensus rating of Hold and a consensus target price of GBX 7,050 ($92.12).

AZN opened at GBX 6,847.69 ($89.48) on Wednesday. The firm has a market capitalization of $89.83 billion and a P/E ratio of 40.00. The stock’s 50 day moving average price is GBX 7,133.74 and its two-hundred day moving average price is GBX 6,387.83. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 7,583 ($99.09).

The company also recently disclosed a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were issued a dividend of GBX 71.90 ($0.94) per share. This represents a dividend yield of 1.07%. The ex-dividend date was Thursday, August 8th. AstraZeneca’s payout ratio is presently 1.28%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: What is a closed-end mutual fund (CEF)?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.